ArticleCurrent oncology (Toronto, Ont.)2023

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.

Ambica Parmar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.